BioMarin Pharmaceutical Inc. followed up its recent announcement of a shift in research and development priorities and a new commercial strategy for its hemophilia A gene therapy Roctavian (valoctocogene roxaparvovec) with a disclosure on 28 August that the company will reduce its global workforce by 225 people in line with its reorganization plans.
Finance Watch: BioMarin Cuts 225 Jobs In Line With Recent Reorganization
Genentech Eliminates 93 Positions In California
Restructuring Edition: BioMarin’s layoffs are associated with strategic shifts announced during its second quarter update. Also, Repare reduced its workforce by 25% as it focused in on clinical-stage programs and Aadi cut 80% of its R&D team to conserve cash after a clinical trial failure.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.